Praxis Precision Medicines (PRAX) Competitors $53.85 -1.09 (-1.98%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$53.86 +0.00 (+0.01%) As of 07/18/2025 07:26 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock PRAX vs. KRYS, AKRO, RNA, PTCT, ACLX, MRUS, ZLAB, SRRK, ACAD, and VKTXShould you be buying Praxis Precision Medicines stock or one of its competitors? The main competitors of Praxis Precision Medicines include Krystal Biotech (KRYS), Akero Therapeutics (AKRO), Avidity Biosciences (RNA), PTC Therapeutics (PTCT), Arcellx (ACLX), Merus (MRUS), Zai Lab (ZLAB), Scholar Rock (SRRK), ACADIA Pharmaceuticals (ACAD), and Viking Therapeutics (VKTX). These companies are all part of the "pharmaceutical products" industry. Praxis Precision Medicines vs. Its Competitors Krystal Biotech Akero Therapeutics Avidity Biosciences PTC Therapeutics Arcellx Merus Zai Lab Scholar Rock ACADIA Pharmaceuticals Viking Therapeutics Krystal Biotech (NASDAQ:KRYS) and Praxis Precision Medicines (NASDAQ:PRAX) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, dividends, valuation, media sentiment, earnings, risk, analyst recommendations and profitability. Do insiders & institutionals hold more shares of KRYS or PRAX? 86.3% of Krystal Biotech shares are owned by institutional investors. Comparatively, 67.8% of Praxis Precision Medicines shares are owned by institutional investors. 13.7% of Krystal Biotech shares are owned by company insiders. Comparatively, 2.7% of Praxis Precision Medicines shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Which has preferable valuation and earnings, KRYS or PRAX? Krystal Biotech has higher revenue and earnings than Praxis Precision Medicines. Praxis Precision Medicines is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKrystal Biotech$290.52M14.67$89.16M$4.1635.45Praxis Precision Medicines$8.12M135.05-$182.82M-$10.72-5.02 Do analysts rate KRYS or PRAX? Krystal Biotech currently has a consensus target price of $213.75, suggesting a potential upside of 44.93%. Praxis Precision Medicines has a consensus target price of $94.11, suggesting a potential upside of 74.77%. Given Praxis Precision Medicines' higher probable upside, analysts plainly believe Praxis Precision Medicines is more favorable than Krystal Biotech.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Krystal Biotech 0 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.00Praxis Precision Medicines 1 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.78 Is KRYS or PRAX more profitable? Krystal Biotech has a net margin of 37.17% compared to Praxis Precision Medicines' net margin of -2,137.48%. Krystal Biotech's return on equity of 14.64% beat Praxis Precision Medicines' return on equity.Company Net Margins Return on Equity Return on Assets Krystal Biotech37.17% 14.64% 13.28% Praxis Precision Medicines -2,137.48%-50.42%-46.74% Which has more volatility & risk, KRYS or PRAX? Krystal Biotech has a beta of 0.67, meaning that its stock price is 33% less volatile than the S&P 500. Comparatively, Praxis Precision Medicines has a beta of 2.6, meaning that its stock price is 160% more volatile than the S&P 500. Does the media favor KRYS or PRAX? In the previous week, Krystal Biotech had 18 more articles in the media than Praxis Precision Medicines. MarketBeat recorded 28 mentions for Krystal Biotech and 10 mentions for Praxis Precision Medicines. Praxis Precision Medicines' average media sentiment score of 0.53 beat Krystal Biotech's score of -0.14 indicating that Praxis Precision Medicines is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Krystal Biotech 11 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Praxis Precision Medicines 1 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryKrystal Biotech beats Praxis Precision Medicines on 12 of the 17 factors compared between the two stocks. Get Praxis Precision Medicines News Delivered to You Automatically Sign up to receive the latest news and ratings for PRAX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PRAX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PRAX vs. The Competition Export to ExcelMetricPraxis Precision MedicinesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.10B$2.93B$5.53B$9.41BDividend YieldN/A2.48%3.76%4.04%P/E Ratio-5.0219.8828.2619.78Price / Sales135.05293.75412.9994.60Price / CashN/A41.8435.8558.18Price / Book2.257.678.115.65Net Income-$182.82M-$55.28M$3.25B$257.97M7 Day Performance6.55%4.87%1.63%3.74%1 Month Performance27.18%13.14%7.62%11.95%1 Year Performance-2.02%3.51%32.74%19.22% Praxis Precision Medicines Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PRAXPraxis Precision Medicines2.4747 of 5 stars$53.85-2.0%$94.11+74.8%-2.0%$1.10B$8.12M-5.02110News CoverageAnalyst ForecastAnalyst RevisionKRYSKrystal Biotech4.5323 of 5 stars$150.41+1.5%$213.75+42.1%-27.6%$4.35B$290.52M36.16210News CoverageInsider TradeAnalyst RevisionAKROAkero Therapeutics3.663 of 5 stars$52.73+2.2%$82.50+56.5%+94.6%$4.20BN/A-27.0430Insider TradeRNAAvidity Biosciences2.4033 of 5 stars$33.57+6.7%$66.35+97.7%-25.2%$4.05B$8.93M-11.19190High Trading VolumePTCTPTC Therapeutics4.3322 of 5 stars$49.46+1.9%$65.00+31.4%+46.0%$3.92B$806.78M7.601,410News CoverageInsider TradeAnalyst RevisionACLXArcellx2.5441 of 5 stars$69.92+1.4%$111.23+59.1%+8.0%$3.85B$76.81M-23.3880Positive NewsMRUSMerus2.1551 of 5 stars$55.62+2.1%$84.64+52.2%+14.4%$3.85B$36.13M-13.6337News CoverageAnalyst DowngradeInsider TradeZLABZai Lab3.3581 of 5 stars$34.28+4.7%$54.28+58.3%+79.9%$3.81B$398.99M-13.771,869Positive NewsGap UpSRRKScholar Rock3.2472 of 5 stars$38.59+3.1%$42.67+10.6%+367.5%$3.66B$33.19M-15.25140Analyst ForecastInsider TradeAnalyst RevisionACADACADIA Pharmaceuticals3.9759 of 5 stars$21.89+4.3%$27.88+27.3%+27.1%$3.66B$957.80M15.98510VKTXViking Therapeutics4.6049 of 5 stars$31.63+1.7%$87.15+175.5%-37.1%$3.55BN/A-27.5020Positive NewsUpcoming Earnings Related Companies and Tools Related Companies Krystal Biotech Competitors Akero Therapeutics Competitors Avidity Biosciences Competitors PTC Therapeutics Competitors Arcellx Competitors Merus Competitors Zai Lab Competitors Scholar Rock Competitors ACADIA Pharmaceuticals Competitors Viking Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PRAX) was last updated on 7/20/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThe big winner of Crypto week?It’s Crypto Week at the White House — and the sector is moving from fringe to full-scale adoption. With Bit...Weiss Ratings | SponsoredThis Could Be the Most Profitable Season of Your LifeInstitutional money is pouring in. Bitcoin ETFs are live. Altcoin adoption is accelerating. This is the sam...Crypto Swap Profits | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredI was wrong about TrumpI made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his ...Porter & Company | SponsoredTurn $1K into $50K with This DeFi GemI've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | SponsoredSteve Jobs' Deathbed Secret Finally LeakedLeaked: Jobs’ Final Apple Project Exposed Bloomberg just leaked details of a secret project Steve Jobs set ...Banyan Hill Publishing | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Praxis Precision Medicines, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Praxis Precision Medicines With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
